Teleo Agents 561b83540b vida: research session 2026-05-07 — 8 sources archived

Pentagon-Agent: Vida <HEADLESS>

2026-05-07 04:14:06 +00:00

16 KiB

Raw Blame History

type	agent	date	status	research_question	belief_targeted
musing	vida	2026-05-07	active	Is the psychiatric competency gap for GLP-1 prescribing being formally addressed by professional societies — and does psychiatry's emerging recognition of GLP-1s as 'psychiatric drugs' change the clinical/non-clinical boundary framework in Belief 2? Secondary: what does the divergence between the matched cohort (195% MDD risk) and within-individual Swedish study (42% protective) mean for how the KB should structure GLP-1 psychiatric safety evidence?	Belief 2 (health outcomes are 80-90% determined by non-clinical factors) — disconfirmation angle: if psychiatry is formally reclassifying GLP-1s as drugs that work THROUGH non-clinical pathways (reward, motivation, addiction circuits), and professional society guidelines are emerging to govern this, then the clinical/non-clinical boundary may be dissolving in a clinically meaningful way — not just at the individual patient level but structurally, across prescribing systems.

Research Musing: 2026-05-07

Session Planning

Tweet feed status: Empty (sixteenth consecutive empty session). Working entirely from active threads and web research.

Active threads from Session 38 (2026-05-06):

GLP-1 anhedonia clinical characterization — formal paper (Q2/Q3 2026?) — SECONDARY
NCT07042672 — behavioral therapy + GLP-1 trial details — still inaccessible — SECONDARY
Psychiatric society guidelines on GLP-1 prescribing — APA, ACLP, Psychopharmacology Institute — PRIMARY TODAY
The within-individual vs. matched cohort divergence — ready to document as formal KB divergence — PRIMARY TODAY
GLP-1 AUD Phase 3 (NCT07218354) — re-check Q3 2026

Why this direction today:

Session 38 established that:

Psychiatry recognizes a "competency gap" — primary care prescribing GLP-1s at therapeutic doses without psychiatric monitoring
Osmind/Psychopharmacology Institute Q1 2026 reviews are signaling professional society awareness
Low-dose tirzepatide (0.6mg) + behavioral context = no anhedonia; this is a prescribing SYSTEM failure, not a pharmacological one
The within-individual vs. matched cohort divergence is ready to write up for the KB

Today's primary questions:

Are APA or ACLP formally issuing GLP-1 prescribing guidelines? This is a structural claim about whether the healthcare system is beginning to address the competency gap.
Has the formal KB divergence been drafted? The evidence is clear — I should document the competing study designs for the extractor.

Keystone Belief disconfirmation target — Belief 2:

"Health outcomes are 80-90% determined by factors outside medical care — behavior, environment, social connection, and meaning."

Today's specific disconfirmation scenario:

If psychiatric professional societies are now formally classifying GLP-1s as psychiatric medications with monitoring protocols, this means clinical medicine is actively being restructured to address non-clinical pathways (reward, motivation, addiction) at scale.
This doesn't refute Belief 2's allocation claim (the system still invests in the 10-20%). But it may complicate the 10-20% figure itself if a single drug class is demonstrably addressing 40-50% of psychiatric outcomes that were previously in the "non-clinical" bucket.
STRONGEST disconfirmation: evidence that the 10-20% clinical care figure is measured against a PRE-GLP-1 baseline and needs to be updated.

Findings

1. Psychiatric Society Guidelines for GLP-1 Prescribing

Search targets: APA guidelines GLP-1 2026, ACLP GLP-1 prescribing guidance, Academy of Consultation-Liaison Psychiatry GLP-1, psychiatric monitoring semaglutide guidelines

Result: NO FORMAL APA/ACLP GUIDELINES EXIST YET — but de facto clinical guidance is emerging through CME bodies.

Key finding: The competency gap is being addressed by continuing medical education pathways rather than formal professional society guidelines:

Psychopharmacology Institute Q1 2026 review is the nearest thing to a formal guidance document for psychiatrists in 2026. Key recommendations:
- FDA removed suicidality warning from GLP-1 labels (January 2026)
- Schizophrenia: prioritize clozapine/olanzapine patients; use HbA1c cutoff 5.4% for early metabolic risk screening
- Monthly monitoring with validated depression/suicidality tools for all psychiatric patients on GLP-1
- Patient and caregiver psychoeducation on mood lability, appetite changes, suicidal ideation
ABOM (American Board of Obesity Medicine) offers certification path (~60 hours CME) but it's not psychiatry-specific
PMHNPs (psychiatric nurse practitioners) are being credentialed by telehealth platforms (Klarity Health) to co-prescribe GLP-1s alongside mental health management — new clinical model
Osmind calling for psychiatry to "get ahead of this" (March 2026) — "Psychiatry Should Start Acting Like It" — but this is advocacy, not guidance
Formal APA or ACLP clinical practice guideline: NOT YET PUBLISHED as of May 2026

Claim candidate: "GLP-1 prescribing competency for psychiatric patients is being addressed through CME infrastructure (Psychopharmacology Institute, ABOM) and telehealth platforms (PMHNP credentialing) rather than formal professional society guidelines — the competency gap is closing informally rather than institutionally."

2. GLP-1 CNS Effects Are Condition-Specific, Not Universal: The EVOKE Failure

The biggest new finding of this session — unexpected, and important:

Semaglutide EVOKE + EVOKE+ Phase 3 trials (Lancet, March 19, 2026):

Design: ~3,800 patients with CONFIRMED Alzheimer's pathology, early symptomatic AD, randomized to oral semaglutide 14mg vs. placebo, 2 years
Primary endpoint: CDR-SB change at week 104 — NO DIFFERENCE from placebo
Secondary endpoint: Activities of Daily Living — NO DIFFERENCE
Biomarker finding: 10% reduction in CSF p-tau181 at week 78 vs. placebo — real but clinically meaningless at this magnitude
Novo Nordisk cancelled the planned 1-year extension
Expert interpretation: The biomarker shift with zero clinical effect suggests the mechanism is too small to overcome Alzheimer's pathological cascade at this dose/stage

Critical nuance: The real-world evidence showing GLP-1 users have lower dementia incidence was confounded by patient population. Real-world GLP-1 users have metabolic disease (obesity, T2D) — the GLP-1 effect may be through METABOLIC RISK REDUCTION, not direct neuroprotection. In EVOKE, patients had confirmed Alzheimer's pathology and no metabolic indication — the confound is eliminated, and the effect disappears.

Parkinson's disease — more promising (but not confirmed at Phase 3):

Motor function improvement (MDS-UPDRS Part III in ON state) in meta-analysis of 5 trials
Mechanistic rationale: PD involves substantia nigra dopaminergic degeneration — the SAME circuits GLP-1 modulates in reward/motivation contexts
Not yet approved; evidence is Phase 2 quality

The key structural insight (UNEXPECTED): GLP-1 appears to work THROUGH behavioral/reward pathways (VTA, nucleus accumbens, dopamine circuits) and AGAINST metabolic drivers of neurological risk — but NOT by directly modifying neurodegeneration at the molecular level. The Alzheimer's failure supports this: where the pathology is amyloid/tau-driven and the patient population lacks metabolic comorbidity, GLP-1 provides no benefit.

Belief 2 implication: This STRENGTHENS Belief 2 in a subtle way. The pattern across GLP-1 CNS studies:

Works WHERE: reward circuits, motivation, compulsive behavior, mood regulation via dopamine — all non-clinical pathway domains
Fails WHERE: progressive neurodegeneration via amyloid/tau pathology — purely molecular/biological disease progression
Biomarker improvement without clinical benefit (Alzheimer's) = molecular correction insufficient without behavioral context change

The Alzheimer's failure suggests GLP-1 is not a universal clinical drug that overrides non-clinical determinants. It's a drug that specifically engages the circuits that bridge clinical and non-clinical pathways (reward, motivation, compulsive behavior). Where non-clinical pathways are NOT the mechanism, GLP-1 fails clinically.

CLAIM CANDIDATE: "Semaglutide fails to slow Alzheimer's progression despite biomarker effects (EVOKE + EVOKE+, Lancet March 2026), distinguishing GLP-1's psychiatric benefits (reward/motivation circuits) from neuroprotective claims that lack causal mechanism."

3. All of Us SUD Study — Large Observational Evidence

Frontiers in Psychiatry (March 10, 2026) — Abegaz et al., nested case-control, All of Us Research Program:

Effect sizes:

Any SUD: OR = 0.25 (75% lower odds) — 95% CI 0.22–0.30
AUD: OR = 0.26 (74% lower odds) — 95% CI 0.20–0.34
OUD: OR = 0.31 (69% lower odds) — 95% CI 0.23–0.42
NUD (nicotine): OR = 0.32 (68% lower odds) — 95% CI 0.27–0.39
CUD (cocaine): OR = 0.25 (75% lower odds) — 95% CI 0.16–0.40

Sample sizes: AUD cohort n=22,652; OUD n=13,226; NUD n=42,320; CUD n=9,296. Propensity score matched 1:1. Observation window 2005–2025.

Key limitation: Observational. No individual GLP-1 drug differentiated (combined liraglutide, semaglutide, exenatide, dulaglutide). Reverse causality possible despite 90-day lag. Unmeasured confounding (psychiatric comorbidity, healthcare-seeking behavior).

What this adds: The EFFECT SIZE is extraordinary (75% lower odds across ALL substance categories). Even with confounding, this is hard to explain entirely as selection bias. This converges with: Lancet Psychiatry Swedish cohort (within-individual, 47% SUD worsening reduction), JAMA Psychiatry AUD RCT (41% reduction in heavy drinking days, NNT 4.3). Three independent designs all pointing in the same direction.

Cross-session pattern update: Now have 3 independent evidence streams for GLP-1 and SUD:

Observational (All of Us, OR=0.25) — strongest effect size, weakest design
Within-individual (Lancet Psychiatry Swedish, 47% reduction) — strongest design, psychiatric subpopulation
RCT (JAMA Psychiatry 2025, 41% reduction, NNT 4.3) — gold standard design, AUD + obesity

4. Semaglutide MDD — Motivation/Effort-Based Decision Making

JAMA Psychiatry, April 29, 2026 — Gill et al., University of Toronto:

Design: 16-week RCT, n=72 (semaglutide n=35, placebo n=37), MDD + BMI ≥25
Drug: oral semaglutide titrated to 14mg
Primary outcome (executive function): NOT improved (p=0.60)
Secondary finding: Semaglutide reduced sensitivity to effort cost vs. reward — patients perceived effort as less costly relative to reward (β = -1.737; P = .03)
Translation: Semaglutide improves MOTIVATION/AVOLITION in MDD — the reduced willingness to exert effort that characterizes depression's anhedonic component
Safe in MDD population

Significance: This is the first RCT directly testing the effort-discounting mechanism in MDD. The negative primary endpoint (executive function) with positive secondary endpoint (effort-based decision-making) maps exactly onto the expected GLP-1 mechanism — it works through reward circuits, not through cognitive architecture. This is the same dissociation as the EVOKE finding: GLP-1 works WHERE the circuit is reward-relevant.

Connection to anhedonia debate: Avolition (effort discounting) IS a core anhedonic symptom. GLP-1 improving it at the therapeutic MDD dose range suggests the dose-dependent anhedonia at WEIGHT LOSS doses is a dosing artifact operating in the opposite direction from the drug's therapeutic effect in depression.

5. Belief 2 Disconfirmation Assessment (Session 39)

Overall verdict: CONFIRMED WITH ADDITIONAL NUANCE — EVOKE failure strengthens rather than weakens Belief 2

The EVOKE failure (unexpected): GLP-1 does NOT cross the clinical/non-clinical boundary for pure neurodegenerative disease (amyloid/tau pathology). It works THROUGH the circuits that already represent the clinical/non-clinical interface (reward, motivation, behavioral drive). Where those circuits aren't relevant to the disease mechanism, GLP-1 fails clinically.

Refined Belief 2 framing:

The 10-20% clinical care figure stands as a SYSTEM-LEVEL claim
GLP-1 is a notable exception — a clinical drug that specifically engages non-clinical pathway circuits
But the EVOKE failure shows this exception is circuit-specific: dopamine/reward/behavioral, NOT molecular disease progression
The exception is smaller than Sessions 37-38 suggested; GLP-1's CNS benefits are mechanistically constrained

Confidence: Belief 2 CONFIRMED with important precision added — the clinical/non-clinical boundary is porous specifically at the reward/motivation interface, not generally.

Follow-up Directions

Active Threads (continue next session)

Novo Nordisk MDD program (formal trials): The 16-week Toronto RCT is encouraging. Look for Phase 2 trial by Novo Nordisk specifically for MDD (with anhedonia endpoints). Search: "Novo Nordisk semaglutide MDD Phase 2 trial anhedonia 2026."
GLP-1 Parkinson's Disease — Phase 3 evidence: Motor function improvement signal from meta-analysis (5 studies) needs Phase 3 confirmation. Search: "semaglutide liraglutide Parkinson's disease Phase 3 RCT 2026" — may have emerged Q1 2026 given AD/PD conference timing.
Formal APA guideline on GLP-1 in psychiatry: The pressure from Osmind + Psychopharmacology Institute Q1 2026 may produce a formal position statement H2 2026. Search in August-September 2026.
GLP-1 schizophrenia metabolic management: Psychopharmacology Institute released specific guidance for schizophrenia patients on clozapine/olanzapine. Fetch the detailed article — may have claims about monitoring protocols and specific screening thresholds. (URL: https://psychopharmacologyinstitute.com/section/glp-1s-in-schizophrenia-should-semaglutide-be-added-for-metabolic-management/)
The within-individual vs. matched cohort divergence — READY TO WRITE as formal KB divergence. Document: Lancet Psychiatry Swedish (within-individual, n=95,490) vs. Nature Scientific Reports (matched cohort, n=162,253). The KB evidence is documented across sessions 37-38-39.

Dead Ends (don't re-run these)

NCT07042672 via ClinicalTrials.gov WebFetch: ClinicalTrials.gov renders CSS/JS, not readable trial data. Dead end. Use Google search "NCT07042672 principal investigator" instead.
Psychiatric Times "Transformation 2.0" article: 403. Don't re-fetch. Summary captured through search results.
OHSU GLP-1 Psychiatry PDF (Mason Allen, MD): Binary PDF — cannot be parsed by WebFetch. Skip.
drlewis.com GLP-1 guidance: 403 error.
APA formal GLP-1 guideline in 2026: Does not exist. The field is using Psychopharmacology Institute CME and Osmind advocacy, not formal APA guidance. Don't search again until late 2026.

Branching Points (this session opened these)

GLP-1 CNS specificity finding (EVOKE failure + MDD success):
- Finding: GLP-1 works through reward/dopamine circuits but NOT through molecular neurodegeneration pathways
- Direction A: Write KB claim: "Semaglutide fails to slow Alzheimer's progression despite biomarker effects, distinguishing GLP-1's psychiatric benefits from neuroprotective claims" — HIGH PRIORITY CLAIM
- Direction B: Write KB claim on GLP-1 reward circuit specificity — the mechanistic bridge between metabolic + psychiatric effects
- Pursue Direction A first (more archivable, more specific, falsifiable)
All of Us SUD study + JAMA Psychiatry AUD RCT + Lancet Psychiatry Swedish cohort convergence:
- Three independent designs now point to GLP-1 reducing SUD risk by 40-75%
- Direction: This is ready to be a HIGH-CONFIDENCE claim (from experimental to likely). The convergence across 3 designs justifies confidence upgrade.
- Evidence: OR=0.25 (All of Us observational), 47% worsening reduction (within-individual), 41% reduction in heavy drinking days (RCT, NNT 4.3)
Competency gap → monitoring protocol structural claim:
- CME-based competency building (not formal guidelines) means the competency gap will close unevenly across the prescriber population
- Direction: This is a Belief 3 (structural misalignment) instance worth writing as a claim about how informal competency building leads to persistent variation in psychiatric monitoring quality for GLP-1 patients

16 KiB Raw Blame History Unescape Escape